Research programme: Ebola and Marburg virus immune globulins - Cangene
Latest Information Update: 28 Feb 2014
At a glance
- Originator Cangene Corporation
- Developer Emergent BioSolutions
- Class Antibodies; Immunoglobulins; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Ebola virus infections; Marburg virus disease
Most Recent Events
- 21 Feb 2014 Cangene Corporation has been acquired and merged into Emergent BioSolutions
- 19 Jun 2007 Development of this programme is ongoing; Cangene is seeking funding for continued development
- 16 Apr 2003 Preclinical trials in Ebola virus infections in Canada (Parenteral)